Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Johnson and Johnson
Harvard Business School
AstraZeneca
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR BUPRENEX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Buprenex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01324544 ↗ Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain Withdrawn Purdue Pharma LP Phase 3 2011-11-01 The purpose of this study is to characterize the safety, pharmacokinetics (PK), and efficacy of intravenous (IV) buprenorphine in pediatric patients.
NCT01407575 ↗ Buprenorphine for Treatment Resistant Depression Completed National Alliance for Research on Schizophrenia and Depression Phase 3 2011-09-01 The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
NCT01407575 ↗ Buprenorphine for Treatment Resistant Depression Completed University of Pittsburgh Phase 3 2011-09-01 The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
NCT01452789 ↗ Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Completed National Institute on Drug Abuse (NIDA) Phase 3 2011-11-01 The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was associated with a ~30% reduction length of treatment compared to standard of care morphine. Due to the subjective nature of the scoring instrument, efficacy in a blinded trial is needed to unequivocally establish the superiority of buprenorphine over morphine. The primary objective of the trial is to compare length of treatment using sublingual buprenorphine or oral morphine solution in the pharmacologic treatment of the NAS.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Buprenex

Condition Name

Condition Name for Buprenex
Intervention Trials
Neonatal Abstinence Syndrome 2
Depression 2
Opioid Dependence 1
Other Acute Postoperative Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Buprenex
Intervention Trials
Neonatal Abstinence Syndrome 3
Depressive Disorder, Major 2
Depressive Disorder 2
Depression 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Buprenex

Trials by Country

Trials by Country for Buprenex
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Buprenex
Location Trials
Pennsylvania 4
Wisconsin 1
Florida 1
Connecticut 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Buprenex

Clinical Trial Phase

Clinical Trial Phase for Buprenex
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
Phase 1/Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Buprenex
Clinical Trial Phase Trials
Completed 4
Recruiting 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Buprenex

Sponsor Name

Sponsor Name for Buprenex
Sponsor Trials
Thomas Jefferson University 2
National Institute of Mental Health (NIMH) 1
Jordan F. Karp 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Buprenex
Sponsor Trials
Other 10
NIH 2
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Mallinckrodt
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.